8-K: ReShape Lifesciences Extends $200,000 Loan to Vyome Therapeutics to Facilitate Merger

ReShape Lifesciences Inc. has provided a $200,000 promissory note to Vyome Therapeutics, Inc. to support working capital and merger-related expenses, advancing their previously announced merger agreement.

Summary

• ReShape Lifesciences Inc. (ReShape) loaned $200,000 to Vyome Therapeutics, Inc. (Vyome) via a promissory note dated June 27, 2025.
• The proceeds from the loan are designated for Vyome's working capital and expenses related to the Agreement and Plan of Merger, dated July 8, 2024, between the parties.
• The outstanding principal balance of the promissory note will bear interest at a rate of 8.0% per annum.
• The aggregate unpaid principal amount and all accrued unpaid interest are due and payable on September 30, 2025.
• If the merger is completed prior to September 30, 2025, Vyome will not be required to repay the outstanding amounts, but the aggregate amount of unpaid principal and interest will be counted as ReShape net cash under the Merger Agreement.
• If the Merger Agreement is terminated by ReShape due to the Concurrent Financing Agreement not being in full force and effect, the promissory note will immediately become senior in right of payment to all other debt of Vyome and will become a secured obligation, with Vyome granting a security interest in all its assets.
• The termination fee under the Merger Agreement is set at $1,000,000, reduced by the total outstanding principal and interest from this note and a prior promissory note dated April 15, 2025.

Sentiment

Score: 6

Explanation: The loan facilitates a strategic merger, which is generally positive for both companies involved. While it represents a financial outlay for ReShape, the terms include interest and potential security, mitigating some risk. The transaction indicates progress towards a larger strategic goal.

Positives

• The loan provides Vyome with necessary working capital and funds for merger-related expenses, potentially facilitating the completion of the strategic merger.
• The promissory note carries an 8.0% annual interest rate, providing a return for ReShape on the loaned funds.
• ReShape gains a senior and secured position on the loan if the merger terminates due to a Concurrent Financing Default by Vyome, offering some downside protection for ReShape's investment.

Negatives

• ReShape is extending a loan, which represents a financial outlay and inherent risk, particularly if the merger does not complete and Vyome defaults on its repayment obligations.
• The loan only becomes senior and secured under specific termination conditions related to the Concurrent Financing, not in all potential default scenarios, limiting ReShape's immediate security.

Risks

• Risk of merger termination, which could impact the repayment terms and the security status of the loan.
• Vyome's ability to repay the loan if the merger is not completed by the September 30, 2025, maturity date.
• The Concurrent Financing Agreement not being in full force and effect, which could trigger the loan's seniority and security provisions but also indicates a potential issue with the merger's financing.
• General risks associated with Vyome's financial health and its capacity to meet its obligations under the promissory note.

Future Outlook

The promissory note is intended to provide Vyome with working capital and cover merger-related expenses, indicating continued progress towards the completion of the merger between ReShape Lifesciences and Vyome Therapeutics. If the merger is completed, the loan will be treated as ReShape net cash under the Merger Agreement.

Management Comments

• ReShape agreed to loan $200,000 to Vyome.
• Vyome will use the proceeds for working capital purposes as well as legal, accounting and other expenses related to the transactions contemplated by the Agreement and Plan of Merger.
• If the merger is completed prior to September 30, 2025, then Vyome will not be required to repay the amounts outstanding under the promissory note, but the aggregate amount of unpaid principal and interest will then be counted as ReShape net cash under the Merger Agreement.

Industry Context

This transaction is typical in the biotechnology and life sciences sectors, where strategic mergers and acquisitions often involve interim financing arrangements to support the target company's operations and cover transaction-related costs during the integration phase. Such loans facilitate deal progression and ensure the target remains operational until closing.

Related Party Transactions

• ReShape Lifesciences Inc. (lender) and Vyome Therapeutics, Inc. (borrower) are parties to a Merger Agreement, making this loan a transaction between related entities in the context of their ongoing strategic combination.

Stakeholder Impact

• Shareholders of ReShape Lifesciences: The loan represents a use of capital, but it is intended to facilitate a strategic merger that could create long-term value. There is a risk of non-repayment if the merger fails.
• Shareholders of Vyome Therapeutics: The loan provides essential funding for operations and merger-related costs, supporting the company's stability and the progression of the merger.
• Creditors of Vyome Therapeutics: The promissory note could become senior and secured to other debt under specific termination conditions, potentially impacting the recovery prospects of other creditors in a default scenario.

Next Steps

• Completion of the merger between ReShape Lifesciences Inc. and Vyome Therapeutics, Inc.
• Repayment of the promissory note by September 30, 2025, if the merger is not completed.
• Potential for the promissory note to become senior and secured if the merger terminates due to a Concurrent Financing Default.

Key Dates

Recommendation

Keywords

ReShape Lifesciences, Vyome Therapeutics, Promissory Note, Merger Agreement, Working Capital, SEC Filing, 8-K, Corporate Finance, Debt Financing, Nasdaq Capital Market, RSLS, Corporate Governance, Risk Management